<table border="single" id="id_1f587ae3-6218-4ad3-af8c-05abb8ad6490" width="497" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption id="id_fb6b3a12-1882-4ed5-be65-ba7dac8c14c1">Table 6. Effect of Other Drugs on Voriconazole Pharmacokinetics  [see Clinical Pharmacology (<linkhtml href="#i4i_section_id_d037e54f-2fc7-4342-875d-561d6da2af9d">12.3</linkhtml>)]</caption>
<col width="33.8%"></col>
<col width="34.4%"></col>
<col width="31.7%"></col>
<tfoot id="id_ee59e8d9-bd29-464e-b55a-7ae872f7bec1">
<tr>
<td align="left" colspan="3" stylecode="Botrule" valign="top">*Results based on <content stylecode="italics">in vivo </content>clinical studies generally following repeat oral dosing with 200 mg q12h voriconazole to healthy subjects<br/>**Results based on <content stylecode="italics">in vivo </content>clinical study following repeat oral dosing with 400 mg q12h for 1 day, then 200 mg q12h for at least 2 days voriconazole to healthy subjects<br/>*** Non-Nucleoside Reverse Transcriptase Inhibitors</td>
</tr>
</tfoot>
<tbody>
<tr id="id_0737f667-2b0d-4c68-8350-8338a79381a0">
<td align="left" stylecode="Botrule Toprule Rrule Lrule" valign="top">
<content stylecode="bold">Drug/Drug Class <br/>(Mechanism of Interaction by the Drug) </content>
</td>
<td align="center" stylecode="Botrule Rrule" valign="top">
<content stylecode="bold">Voriconazole Plasma Exposure <br/>(C<sub>max</sub> and AUC</content>τ<content stylecode="bold"> after 200 mg q12h) </content>
</td>
<td align="center" stylecode="Botrule Rrule" valign="top">
<content stylecode="bold">Recommendations for Voriconazole Dosage Adjustment/Comments </content>
</td>
</tr>
<tr id="id_b0c6f1e2-2ab9-42de-9ba4-1acf338a16dd">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">Rifampin* and Rifabutin* <br/>(CYP450 Induction) </td>
<td align="center" stylecode="Botrule Rrule" valign="top">Significantly Reduced </td>
<td align="center" stylecode="Botrule Rrule" valign="top">
<content stylecode="bold">Contraindicated </content>
</td>
</tr>
<tr id="id_6b1b4d47-fdab-4216-8c40-5c85a368d085">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">Efavirenz** <br/>(CYP450 Induction) </td>
<td align="center" stylecode="Botrule Rrule" valign="top">Significantly Reduced </td>
<td align="center" stylecode="Botrule Rrule" valign="top">When voriconazole is coadministered with efavirenz, voriconazole oral maintenance dose should be increased to 400 mg q12h and efavirenz should be decreased to 300 mg q24h </td>
</tr>
<tr id="id_cabe1428-296c-4fbf-a21c-ad01880fcfcd">
<td align="left" stylecode="Lrule Rrule" valign="top">
<paragraph>High-dose Ritonavir (400 mg q12h)** (CYP450 Induction) </paragraph>
</td>
<td align="center" stylecode="Rrule" valign="top">
<paragraph>Significantly Reduced</paragraph>
</td>
<td align="center" stylecode="Rrule" valign="top">
<paragraph>
<content stylecode="bold">Contraindicated</content>
</paragraph>
</td>
</tr>
<tr id="id_99d6fcfa-9059-44af-aa74-504517d2b8bd">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">Low-dose Ritonavir (100 mg q12h)** (CYP450 Induction) </td>
<td align="center" stylecode="Botrule Rrule" valign="top">
<paragraph>Reduced</paragraph>
</td>
<td align="center" stylecode="Botrule Rrule" valign="top">
<paragraph>Coadministration of voriconazole and low-dose ritonavir (100 mg q12h) should be avoided, unless an assessment of the benefit/risk to the patient justifies the use of voriconazole </paragraph>
</td>
</tr>
<tr id="id_62d1f459-00e8-426a-8d80-61227b6e5788">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">Carbamazepine <br/>(CYP450 Induction) </td>
<td align="center" stylecode="Botrule Rrule" valign="top">Not Studied <content stylecode="italics">In Vivo</content> or <content stylecode="italics">In Vitro</content>, but Likely to Result in Significant Reduction </td>
<td align="center" stylecode="Botrule Rrule" valign="top">
<content stylecode="bold">Contraindicated </content>
</td>
</tr>
<tr id="id_2115a117-2418-42de-9885-3f9f2d8fa374">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">Long Acting Barbiturates <br/>(CYP450 Induction) </td>
<td align="center" stylecode="Botrule Rrule" valign="top">Not Studied <content stylecode="italics">In Vivo</content> or <content stylecode="italics">In Vitro</content>, but Likely to Result in Significant Reduction </td>
<td align="center" stylecode="Botrule Rrule" valign="top">
<content stylecode="bold">Contraindicated </content>
</td>
</tr>
<tr id="id_d3ef58b1-6037-4996-93d4-5f0c28c79f06">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">Phenytoin*<br/>(CYP450 Induction) </td>
<td align="center" stylecode="Botrule Rrule" valign="top">Significantly Reduced </td>
<td align="center" stylecode="Botrule Rrule" valign="top">Increase voriconazole maintenance dose from 4 mg/kg to 5 mg/kg IV q12h or from 200 mg to 400 mg orally q12h (100 mg to 200 mg orally q12h in patients weighing less than 40 kg) </td>
</tr>
<tr id="id_2bc0d65d-138b-4828-8f5f-ad6359cbd49a">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">St. John’s Wort <br/>(CYP450 inducer; P-gp inducer) </td>
<td align="center" stylecode="Botrule Rrule" valign="top">Significantly Reduced </td>
<td align="center" stylecode="Botrule Rrule" valign="top">
<content stylecode="bold">Contraindicated </content>
</td>
</tr>
<tr id="id_9a3570c7-58ac-45a9-8517-21bbba90a9d7">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">Oral Contraceptives** <br/>containing ethinyl estradiol and norethindrone (CYP2C19 Inhibition) </td>
<td align="center" stylecode="Botrule Rrule" valign="top">Increased </td>
<td align="center" stylecode="Botrule Rrule" valign="top">Monitoring for adverse events and toxicity related to voriconazole is recommended when coadministered with oral contraceptives </td>
</tr>
<tr id="id_aa5a3b5d-2b01-4bfd-bc4a-9c2ed63379dc">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">Fluconazole** (CYP2C9, CYP2C19 and CYP3A4 Inhibition) </td>
<td align="center" stylecode="Botrule Rrule" valign="top">Significantly Increased </td>
<td align="center" stylecode="Botrule Rrule" valign="top">Avoid concomitant administration of voriconazole and fluconazole. Monitoring for adverse events and toxicity related to voriconazole is started within 24 h after the last dose of fluconazole. </td>
</tr>
<tr id="id_81c0962a-b4a9-4c8c-bd3f-01842d7f40e1">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">Other HIV Protease Inhibitors <br/>(CYP3A4 Inhibition) </td>
<td align="center" stylecode="Botrule Rrule" valign="top">
<paragraph>
<content stylecode="italics">In Vivo</content> Studies Showed No Significant Effects of Indinavir on Voriconazole Exposure <br/>
</paragraph>
<content stylecode="italics">In Vitro</content> Studies Demonstrated Potential for Inhibition of Voriconazole Metabolism (Increased Plasma Exposure) </td>
<td align="center" stylecode="Botrule Rrule" valign="top">
<paragraph>No dosage adjustment in the voriconazole dosage needed when coadministered with indinavir </paragraph>Frequent monitoring for adverse events and toxicity related to voriconazole when coadministered with other HIV protease inhibitors </td>
</tr>
<tr id="id_f9756538-72c2-43fc-9c28-caa5e27fc6f3">
<td align="left" stylecode="Lrule Rrule" valign="top">
<paragraph>Other NNRTIs*** </paragraph>(CYP3A4 Inhibition or CYP450 Induction) </td>
<td align="center" stylecode="Rrule" valign="top">
<paragraph>
<content stylecode="italics">In Vitro</content> Studies Demonstrated Potential for Inhibition of Voriconazole Metabolism by Delavirdine and Other NNRTIs (Increased Plasma Exposure)</paragraph>
</td>
<td align="center" stylecode="Rrule" valign="top">
<paragraph>Frequent monitoring for adverse events and toxicity related to voriconazole</paragraph>
</td>
</tr>
<tr id="id_f5bdfa16-820d-4588-99dd-fff2622c92e2">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top"></td>
<td align="center" stylecode="Rrule" valign="top">A Voriconazole-Efavirenz Drug Interaction Study Demonstrated the Potential for the Metabolism of Voriconazole to be Induced by Efavirenz and Other NNRTIs (Decreased Plasma Exposure) </td>
<td align="center" stylecode="Botrule Rrule" valign="top">Careful assessment of voriconazole effectiveness </td>
</tr>
</tbody>
</table>